Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ).
Daito Pharmaceutical Co., Ltd. has repurchased 77,200 shares of its common stock on the Tokyo Stock Exchange between February 1 and February 28, 2026, for a total of 103,725,900 yen. This buyback is conducted under the authority of its Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act of Japan.
The repurchase is part of a broader program approved by the board on October 10, 2025, authorizing the buyback of up to 1,000,000 shares or 1,500 million yen through May 22, 2026. As of February 28, 2026, the company has cumulatively repurchased 674,400 shares for 875,078,500 yen, signaling ongoing shareholder return efforts and potential support for its share price and capital efficiency metrics.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1536.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd., listed on the Prime Market of the Tokyo Stock Exchange under securities code 4577, operates in the pharmaceutical industry. The company focuses on developing and supplying pharmaceutical products, positioning itself within Japan’s healthcare market as a publicly traded drug maker with an active capital market presence.
Average Trading Volume: 75,299
Technical Sentiment Signal: Buy
Current Market Cap: Yen44.23B
See more insights into 4577 stock on TipRanks’ Stock Analysis page.